Brief: Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition With Prp In Pancreatic Cancer Models, Contrasting Profile With Revolution Medicines’ Daraxonrasib
07/10/2026 13:44
BRIEF-Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition With Prp In Pancreatic Cancer Models, Contrasting Profile With Revolution Medicines’ Daraxonrasib Oct 7 (Reuters) - Propanc Biopharma Inc PPCB.O:
PROPANC BIOPHARMA REPORTS DATA SHOWING 90% TUMOR GROWTH INHIBITION WITH PRP IN PANCREATIC CANCER MODELS, CONTRASTING PROFILE WITH REVOLUTION MEDICINES’ DARAXONRASIB
PROPANC BIOPHARMA - PRP SHOWS MARKED REDUCTION IN METASTATIC BURDEN IN PDAC MODELS
PROPANC BIOPHARMA - TO START OPEN-LABEL PHASE 1B STUDY OF PRP IN Q1 2027 ENROLLING UP TO 50 PATIENTS
Source text: ID:nGNX60sv9M
Further company coverage: PPCB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Propanc Biopharma
See all newsNASDAQ TRADE HALT HALT NEWS PENDING AT 09:29 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition With Prp In Pancreatic Cancer Models, Contrasting Profile With Revolution Medicines’ Daraxonrasib
Brief: Propanc Biopharma Registers Resale Of 6,500,000 Shares Of Common Stock - SEC Filing
Brief: Propanc Biopharma To File Cta In Australia For Phase 1B Study In 30–40 Advanced Cancer Patients